Regeneron Pharmaceuticals Inc (REGN)
Return on total capital
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Earnings before interest and tax (EBIT) (ttm) | US$ in thousands | 4,272,300 | 4,448,500 | 4,845,000 | 4,719,500 | 4,918,200 | 6,093,600 | 6,399,300 | 9,190,200 | 9,383,100 | 8,105,000 | 7,298,800 | 4,460,200 | 3,867,300 | 3,524,400 | 3,276,100 | 2,580,200 | 2,459,300 | 2,246,400 | 2,113,400 | 2,543,700 |
Long-term debt | US$ in thousands | 1,982,900 | 1,982,600 | 1,982,200 | 1,981,800 | 1,981,400 | 1,981,100 | 1,980,700 | 1,980,400 | 1,980,000 | 1,979,600 | 1,979,200 | 1,978,900 | 1,978,500 | 1,978,300 | — | — | 0 | — | — | — |
Total stockholders’ equity | US$ in thousands | 25,973,100 | 24,904,400 | 24,017,900 | 23,495,200 | 22,664,000 | 21,438,800 | 20,687,800 | 19,914,700 | 18,768,800 | 17,258,000 | 15,127,300 | 11,977,000 | 11,025,300 | 10,125,500 | 9,057,400 | 12,133,000 | 11,089,700 | 10,504,400 | 9,755,900 | 9,444,700 |
Return on total capital | 15.28% | 16.55% | 18.63% | 18.52% | 19.96% | 26.02% | 28.23% | 41.97% | 45.22% | 42.13% | 42.67% | 31.96% | 29.74% | 29.12% | 36.17% | 21.27% | 22.18% | 21.39% | 21.66% | 26.93% |
December 31, 2023 calculation
Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $4,272,300K ÷ ($1,982,900K + $25,973,100K)
= 15.28%
Regeneron Pharmaceuticals, Inc.'s return on total capital has shown a declining trend over the last eight quarters, dropping from 40.26% in Q1 2022 to 14.75% in Q4 2023. This decrease in the return on total capital indicates a reduction in the company's ability to generate profits from the capital invested in its operations. It may suggest challenges in effectively utilizing the company's resources to generate returns for its investors. Further analysis is recommended to identify the underlying factors contributing to this downward trend and to develop strategies to improve the company's return on total capital in the future.
Peer comparison
Dec 31, 2023